CAS:132810-10-7 C23H30FN3 Blonanserin

Min.Order / FOB Price:Get Latest Price

500 Gram	Negotiable

500 Gram

Negotiable

Min.Order :500 Gram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

CAS:132810-10-7 C23H30FN3 Blonanserin CAS:132810-10-7 C23H30FN3 factory price high purity 99% CAS:132810-10-7 C23H30FN3 technical grade or OLED grade

Quick Details

Appearance:white poweder
Application:CAS:132810-10-7 C23H30FN3 technical grade or OLED grade
PackAge:Plastic vacuum packaging bag or bucket
ProductionCapacity:1|Metric Ton|Day
Storage:under the cool and dry area
Transportation:by express or by sea

Superiority:

Blonanserin Basic information

Outline Synthesis method Atypical antipsychotic drugs China Patent Information Application

Product Name:	Blonanserin
Synonyms:	CYCLOOCTA[B]PYRIDINE, 2-(4-ETHYL-1-PIPERAZINYL)-4-(4-FLUOROPHENYL)-5,6,7,8,9,10-HEXAHYDRO-;Blonanserin;AD 5423;2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;2-(4-Ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;Lonasen;Blonansarin –;Blonanserin, AD-5423, Lonasen
CAS:	132810-10-7
MF:	C23H30FN3
MW:	367.5028032
EINECS:
Product Categories:	APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	132810-10-7.mol

Blonanserin Chemical Properties

mp	117-119°C
storage temp.	Refrigerator

Safety Information

Hazard Codes	Xn
Risk Statements	22

MSDS Information

Blonanserin Usage And Synthesis

Outline	This product is a serotonin and dopamine antagonist (SDA), it is a second-generation atypical antipsychotic drugs, and has a considerable dopamine D2 receptor blocking action as haloperidol , it also has a strong 5-HT2A blocking effect, the selectivity on both receptors is stronger than other antipsychotics. It displays fewer extrapyramidal response side effects than conventional antipsychotics on the market . It is developed and sold by Sumitomo Pharmaceutical Co., Ltd. of Japan. Listing: April 2008 in Japan.
Synthesis method	Fluorobenzoate condensates with acetonitrile to get fluorobenzoyl acetonitrile, prepared in polyphosphoric acid by the reaction of 3- (4-fluorophenyl) -3-oxo-propionamide, and cyclooctanone cyclization of 4- (4-fluorophenyl) -5,6,7,8,9,10-hexahydro-cyclooctane and [b] pyridin -2 (1H) - one, and recrystallized from benzene dichloride Lin acid dichloride with N- ethylpiperazine nucleophilic substitution to give antipsychotic blonanserin, the overall yield is about 42%. Author: Junfang Wang, Xiaomei Wang , Zhefeng Wang , Huilin Shi Author unit: Shanghai Institute of Pharmaceutical Industry Journal Name: Chinese Journal of Pharmaceuticals 2009 40 (4)
Atypical antipsychotic drugs	Schizophrenia is a common psychiatric disease, since the early 1950s, for the discovery of antipsychotic effects of chiorpromazinum. Schizophrenia has been treated with drugs. According to receptor blocking actions, the commonly used antipsychotics are divided into two categories, naming the typical and atypical: typical antipsychotics are represented by chlorpromazine and haloperidol . The main mechanism is blocking dopamine receptors, it has a good effect on positive symptoms of schizophrenia (hallucinations, delusions, agitation, impulsive behavior, etc.) . Meanwhile extrapyramidal effects (EPS) are common, while the effects for negative symptoms (apathy, poverty of thought, will decline, etc.) are poor, while atypical antipsychotics show a wider spectrum for the treatment of negative symptoms better than traditional medicine, and it is safe, with more mild side effects, the dosage is smaller, there have been many more advanced forms, which greatly improve patient compliance, representative drugs include clozapine, risperidone, olanzapine . Double-blind clinical trials for 8 weeks for blonanserin comparison with haloperidol shown, 263 patients with schizophrenia were involved. 8-24mg / day blonanserin is at least effective as 4-12mg / day of haloperidol, it can improve the final grade improvement rate(FGIR) score (at least two drugs in patients with moderate improvement rate of 61.2% and 51.3%, respectively), less incidence of extrapyramidal side effects (52.7% and 75.4%). The above information is edited by the chemicalbook of Tian Ye.
China Patent Information	January 2008 blonanserin was developed and sold by Sumitomo Pharmaceutical Co., Ltd. of Japan. This product was compound patent in 1989 . The patent has expired. At present, the domestic product is not imported, according to the "Patent Law" and "Regulations on Administrative Protection Drugs" , the drug patent risk does not exist in China, it does not have the conditions of application for administrative protection.
Application	Mental
Chemical Properties	Pale Yellow Solid
Usage	Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 (Ki, 14.8 nM) and serotonin 5-HT2(Ki, 3.98 nM) receptors antagonist properties.
Usage	A 5-HT2 Serotonin receptor and D2 Dopamine receptor antagonist, used as an antipsychotic.

Details:

Blonanserin

Synonyms 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
CAS NO:132810-10-7
Molecular Formula: C₂₃H₃₀FN₃
Molecular Weight: 367.502
Relative density: 1.095g/cm3
Specifications:The enterprise standard =98%
Package:5kg/TIN,25kg/Drum

View All

Visit Store

CAS:132810-10-7 C23...